New York Times: “For Robert F. Kennedy Jr., the activist whom President-elect Donald J. Trump will nominate to serve as the secretary of health and human services, the solution to obesity in America — now at 40 percent of adults — is straightforward: ‘The first line of response should be lifestyle,’ he told Jim Cramer in a Dec. 12 interview on CNBC.”
“Elon Musk, the technology billionaire who advises the president-elect, sees things differently: ‘Nothing would do more to improve the health, lifespan and quality of life for Americans than making GLP inhibitors super low cost to the public,’ he wrote on X, referring to the new class of drugs that cause weight loss, including Ozempic. ‘Nothing else is even close.’”
“And there, with the contrasting views of two men in Mr. Trump’s ear, lie two sides of an issue that is plaguing health and nutrition researchers.”
